OBJECTIVE To describe disparities in prescribing and dispensing sodium–glucose cotransporter 2 inhibitors (SGLT2i) in Israel. RESEARCH DESIGN AND METHODS This was a population-based retrospective cohort study of adults with type 2 diabetes eligible for SGLT2i treatment from 2017 to 2023. The primary outcome was the time between initial eligibility and the first prescription of SGLT2i. RESULTS Among 32,742 eligible patients, only 53% were prescribed SGLT2i. Multivariable analyses, adjusting for death as a competing risk, revealed delays in prescription were associated with older age, Arab or Bedouin ethnicity, neoplasms, acute kidney failure, falls, previous hospitalization, urinary tract infections, and dementia. Factors associated with shorter time intervals to prescription were sex (men), medium/high socioeconomic status, and residing in an intermediate or central area of Israel. CONCLUSIONS Disparities in drug prescription exist, even in a country with universal health coverage. Addressing these disparities requires improvements in health care systems, education, and alert systems to overcome barriers to evidence-based interventions.

中文翻译：

---

以色列人群钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂处方和配药的差异——一项回顾性队列研究

目的 描述以色列钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 处方和配药方面的差异。研究设计和方法 这是一项基于人群的回顾性队列研究，研究对象为 2017 年至 2023 年符合 SGLT2i 治疗资格的 2 型糖尿病成人患者。主要结果是从最初符合资格到首次开具 SGLT2i 处方之间的时间。结果 在 32,742 名符合条件的患者中，只有 53% 的患者服用了 SGLT2i。将死亡作为竞争风险进行调整后的多变量分析显示，延迟处方与年龄较大、阿拉伯或贝都因种族、肿瘤、急性肾衰竭、跌倒、既往住院史、尿路感染和痴呆有关。与较短的处方时间间隔相关的因素是性别（男性）、中/高社会经济地位以及居住在以色列的中间或中心地区。结论 即使在全民健康覆盖的国家，药物处方也存在差异。解决这些差异需要改善医疗保健系统、教育和警报系统，以克服循证干预措施的障碍。